Aarkstore Enterprise - Hepatitis Therapeutics Market to 2016
Posted Nov 18 2010 7:16am
Aarkstore announce a new report "Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market" through its vast collection of market research report.
“Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market. The report analyzes the markets for hepatitis therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.
GBI Research finds that the global hepatitis therapeutics market is one of the growing markets of the pharmaceutical business. Due to the approval of potential new drugs as well as combinational therapies, the hepatitis market will grow further. Launch of drugs with significant efficacy, safety and resistance profiles will fuel rapid uptake of drugs in near future. The limitations of current standard care therapy for hepatitis due to high incidence of adverse events, long duration of treatment, suboptimal patient compliance, lack of efficacy in specific genotypes has increased interest in developing novel products that can probably counter the unmet needs presented by the present market. However, the market sales growth is expected to slow down marginally due to the declining hepatitis incidence rates (use of vaccines), public awareness, and patent expiries of key therapeutics. Nevertheless, the global hepatitis market is still forecasted to grow at a compound annual growth rate (CAGR) of 3.1% between 2001 and 2009.
- Annualized market data for the hepatitis therapeutics market from 2001 to 2009, forecast forward to 2016. - Analysis of the leading therapeutic segments, including hepatitis A, hepatitis B and hepatitis C. - Analysis of the hepatitis therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan. - Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns. - Key drivers and barriers that have a significant impact on the market. - Coverage of pipeline molecules in various phases of drug development. - Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche. - Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global hepatitis therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to : - Align your product portfolio to the markets with high growth potential. - Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth. - Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety. - Develop key strategic initiatives by understanding the key focus areas of leading companies. - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.